Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. (CGTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cgtx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cognition Therapeutics, Inc. (CGTX) measures how much investors pay for each dollar of the company's trailing earnings. CGTX's current PE ratio of N/A is calculated by dividing its stock price of $1.21 by its TTM earnings per share of -$0.22.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2019 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cognition Therapeutics, Inc.You CGTX | $89M | N/A | — | -$0.22 |
 Agenus Inc. AGEN | $131M | 811.87x | +94.5% | $0.00 |
 Atossa Therapeutics, Inc. ATOS | $39M | N/A | — | -$4.04 |
 Greenwich LifeSciences, Inc. GLSI | $318M | N/A | — | -$1.43 |
 Opus Genetics, Inc. IRD | $328M | N/A | — | -$0.08 |
 Seres Therapeutics, Inc. MCRB | $61M | 23.14x | -94.5% | $0.64 |
 Seer, Inc. SEER | $98M | N/A | — | -$1.28 |
Industry Average 2 peers with valid PE | — | 417.51x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.32 | — | |
2024-12-31 FY2024 | — | $-0.86 | — | |
2023-12-31 FY2023 | — | $-0.86 | — | |
2022-12-31 FY2022 | 80.43x | $0.03 | — | |
2021-12-31 FY2021 | — | $-0.53 | — | |
2020-12-31 FY2020 | — | $-0.46 | — | |
2019-12-31 FY2019 | — | $-0.32 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cognition Therapeutics, Inc. (CGTX) measures how much investors pay for each dollar of the company's trailing earnings. CGTX's current PE ratio of N/A is calculated by dividing its stock price of $1.21 by its TTM earnings per share of -$0.22.
Frequently asked questions
CGTX pe ratio · 6 questionsCGTX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.21 and TTM EPS of -$0.22. Data sourced from Financial Modeling Prep via CGTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cognition Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09